慢性鼻窦炎患者报告结局量表中文版的跨文化调适与验证:健康相关生活质量评估
本研究将慢性鼻窦炎患者报告结局量表(CRS-PRO)翻译为中文并进行文化调适,纳入168例慢性鼻窦炎患者(118例伴鼻息肉、50例不伴鼻息肉)和43名健康人,术前及术后3、6个月完成CRS-PRO、SNOT-22和EQ-5D问卷。中文版CRS-PRO内部一致性良好(Cronbach's α=0.813),效标效度优于SNOT-22(r=0.65,p<0.05),能区分患者与健康人及两种亚型(p<0.01),反应性效应量大于SNOT-22。
要点
- 中文版CRS-PRO内部一致性Cronbach's α为0.813,效标效度r=0.65(p<0.05),优于SNOT-22。
- CRS-PRO可区分CRS患者与健康人及CRSwNP与CRSsNP亚型,均p<0.01。
- 术后3、6个月CRS-PRO变化效应量Cohen's d=1.05和0.93,大于SNOT-22的0.71和0.90(均p<0.01)。
核心结论
- 中文版CRS-PRO是一种简明、可靠且反应性良好的工具,可作为未来临床实践中的新型主观评估工具。
研究设计与样本
- 通过正译-回译及文化调适形成中文版CRS-PRO,纳入168例CRS患者(118例CRSwNP和50例CRSsNP)及43名健康人。
- 所有参与者在术前及术后3、6个月完成CRS-PRO、SNOT-22和EQ-5D问卷。
主要发现
- 中文版CRS-PRO内部一致性Cronbach's α为0.813。
- CRS-PRO效标效度r=0.65(p<0.05),高于SNOT-22。
- CRS-PRO与Lund-Mackay评分及内镜评分等客观指标呈中等关联。
- CRS-PRO能区分CRS患者与健康人(p<0.01),也能区分CRSwNP与CRSsNP亚型(p<0.01)。
- 术后3和6个月CRS-PRO变化的效应量Cohen's d分别为1.05和0.93,SNOT-22分别为0.71和0.90(均p<0.01)。
临床怎么用
- 作者认为中文版CRS-PRO可作为未来临床实践中的新型主观评估工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The chronic rhinosinusitis patient-reported outcome (CRS-PRO) is a recently published disease-specific questionnaire designed for CRS patients, with fewer entries and ease of completion. This study aimed to translate the CRS-PRO questionnaire into Chinese and assess its reliability, validity, and responsiveness to provide Chinese patients with a more concise and efficient subjective assessment instrument. METHODS: The Chinese version of the CRS-PRO was created through forward-backward translations and cultural adaptation. Here, 168 CRS patients (118 patients CRS with nasal polyps [CRSwNP] and 50 patients with CRS without nasal polyps [CRSsNP]) and 43 healthy individuals were enrolled. All participants completed the CRS-PRO, 22-item Sinonasal Outcome Test (SNOT-22), and EuroQol five dimensions questionnaire (EQ-5D) questionnaires preoperatively as well as 3 and 6 months after surgery. RESULTS: The Chinese version of the CRS-PRO demonstrated good internal consistency, with a Cronbach's α of 0.813. It also exhibited a higher criterion validity (r = 0.65, p < 0.05) than the SNOT-22. A moderate association was found between the CRS-PRO and objective indicators such as the Lund-Mackay and endoscopic scores. Furthermore, the CRS-PRO, like the SNOT-22, could clearly distinguish CRS patients from healthy subjects (p < 0.01), as well as between the CRSwNP and CRSsNP subtypes (p < 0.01). Additionally, changes in the CRS-PRO exhibited a larger effect size compared to changes in the SNOT-22 (Cohen's d = 1.05 and 0.93 vs. 0.71 and 0.90 for 3 and 6 months, respectively, all p < 0.01). CONCLUSIONS: The Chinese version of the CRS-PRO is a concise, reliable, and responsive instrument that can be utilized as a novel subjective evaluation tool for future clinical practice.
引用
- Chen J, Hu L, Zhang C, et al. Chinese adaptation and validation of the chronic rhinosinusitis-patient-reported outcome: Assessment of health-related quality-of-life. Int Forum Allergy Rhinol. 2023. PMID: 37823234. doi:10.1002/alr.23285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。